AI Generated Image
GLP-1 Weight Loss Drug Use Triples, as Obesity Declines
Newser • • health
Key Points:
- A Gallup survey reveals that 11% of US adults currently use GLP-1 drugs like Ozempic, Wegovy, or Zepbound for weight loss, a significant increase from 3% two years ago.
- Approximately 15% of adults have used these medications at some point, reflecting a 9 percentage point rise in usage over the past two years.
- Awareness of GLP-1 drugs has grown to 91%, up from 80% in 2024, coinciding with a slight decline in self-reported obesity rates from 39.9% in 2022 to 36.4% this year.
- Brand-name GLP-1 drugs from companies like Novo Nordisk and Eli Lilly remain dominant, making up 68% of current use, but cheaper compounded versions are increasingly popular despite FDA warnings about their risks.
- The rise in GLP-1 drug use corresponds with stable diabetes rates at about 13.5%, highlighting a growing trend in medication-assisted weight loss.
